Back
Compare AU
Compare CURE vs. GLOB
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Barrow Hanley Global Share Active ETF (GLOB). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | GLOB | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 78 | 9 |
Median incremental investment | $683.16 | $1,500.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,376.56 | $3,632.68 |
Average age group | > 35 | > 35 |
Key Summary
CURE | GLOB | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 51.24m in AUM and 148 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | GLOB.AX was created on 2022-06-06 by Barrow Hanley. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide investors with long-term capital growth through investment in quality global shares and to outperform the MSCI World Net Total Return Index (AUD) (before fees and taxes) over rolling three-year periods. |
Top 3 holdings | Moderna Inc (3.01 %) Twist Bioscience Corp (1.78 %) Halozyme Therapeutics Inc (1.43 %) | GE HealthCare Technologies Inc Common Stock (3.24 %) Hewlett Packard Enterprise Co (2.95 %) Chevron Corp (2.42 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Health Care (22.78 %) Financials (21.23 %) Industrials (19.81 %) |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | United States (53.45 %) United Kingdom of Great Britain and Northern Ireland (7.51 %) China (5.12 %) |
Management fee | 0.45 % | 0.99 % |
Key Summary
CURE | GLOB | |
|---|---|---|
Issuer | Global X | Barrow Hanley |
Tracking index | S&P Biotechnology Select Industry | MSCI World Index |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.99 % |
Price | $77.92 | $4.61 |
Size | $50.449 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.03 % | 7.97 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 05/06/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | GLOB | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 78 | 9 |
Median incremental investment | $683.16 | $1,500.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,376.56 | $3,632.68 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | GLOB | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | GLOB |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |